Coya Therapeutics partners with Dr. Reddy’s for neurodegenerative disease therapy development
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking ... Read More
Dr. Reddy’s Laboratories introduces FDA-approved Nerivio for migraine management in India
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the rollout of Nerivio in India. This state-of-the-art, United States Food and Drug Administration (USFDA) ... Read More
Dr. Reddy’s Q2 FY24 financial results show 9% YoY revenue growth
Dr. Reddy’s Laboratories Ltd., an Indian pharma major, has unveiled its robust performance metrics for the Q2 FY24, ending September 30, 2023. Under the guidelines ... Read More
Dr. Reddy’s Laboratories debuts generic version of KOMBIGLYZE XR in US
In a significant development for diabetes treatment in the U.S., Dr. Reddy's Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces ... Read More
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More
Dr. Reddy’s launches RGenX to enter trade generics business in India
Dr. Reddy's Laboratories, an Indian pharmaceutical company, has announced its entry into the trade generics business in India with the launch of a dedicated division ... Read More
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a ... Read More
Dr. Reddy’s Laboratories rolls out Regadenoson Injection in US
Indian pharma company Dr. Reddy's Laboratories said that it has launched Regadenoson Injection 0.4 mg/5 mL in the US market. Approved by the US Food ... Read More
Eris Lifesciences strikes deal for Dr. Reddy’s cosmetic dermatology brands
Eris Lifesciences has announced the acquisition of nine cosmetic dermatology brands in the Indian market from Dr. Reddy's Laboratories for INR 275 crores in cash. ... Read More
Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio
Dr. Reddy's Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth ... Read More